checkAd

     132  0 Kommentare Sonoma Pharmaceuticals Announces Expansion of its Partner Network for Oral and Dental Products in the U.S. and China

    Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, disinfectant use and dermatological conditions, today announced that it has added Salus Medical as an additional distribution partner in the United States for dental care and expanded its oral and dental care lines to China via a partnership deal with Anlicare International.

    Sonoma entered into a non-exclusive agreement with Salus Medical to distribute Endocyn root canal irrigant through their existing dental channels. In addition, Salus Medical will expand on their cutting-edge dermatology offerings with Sonoma’s Microcyn RX and Regenacyn Plus products and have non-exclusive distribution rights for Microcyn wound care products.

    “We believe Endocyn root canal irrigant will be a great addition to our product portfolio at Salus Medical. Both Endocyn and the Microcyn line of products fit with our strategy of being dedicated to delivering value to the U.S. healthcare system while combining quality and economy,” said Hernan Alvarez, President of Salus Medical.

    Additionally, on January 18, 2022, Sonoma and Anlicare agreed to cooperate to complete the regulatory work necessary to obtain licenses in China to distribute Sonoma’s Microcyn technology-based dental and oral products. Anlicare will bear the regulatory costs and in return, Sonoma agreed to grant Anlicare exclusive rights for selling and distributing oral and dental care products in China.

    “We see the strength of Sonoma’s Microcyn technology in the prevention of infection and reduction of bacteria and microorganisms and believe Sonoma’s Microcyn technology will be beneficial for dentistry and general oral care for both professional and consumer use,” commented Sherwin Hu, CEO at Anlicare International.

    “We are pleased to add Salus Medical and Anlicare to our growing network of distributors for our oral and dental products, and we continue to seek distribution partners for our proprietary Microcyn technology that is truly superior in terms of antimicrobial impact, shelf stability and safety,” said Bruce Thornton, COO of Sonoma Pharmaceuticals.

    About Salus Medical

    Since 2012, Salus Medical is a national wholesale distributor based in Phoenix, Arizona. As generic wholesaler or generic pharmaceutical distributor, Salus Medical has been focused on delivering economy and value to its clients. Due to its focus on client’s needs, Salus Medical has experienced tremendous growth within its short history. As Salus Medical has developed over the years, it has formed strategic relationships with a wide variety of suppliers nationwide, enabling Salus Medical to supply a range of low-cost yet high-quality products. By offering a broad portfolio of products, Salus Medical is able to service multiple medical facilities and providers within the healthcare continuum including pharmacies, clinics, surgery centers, and hospitals.

    Seite 1 von 3


    Diskutieren Sie über die enthaltenen Werte


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Sonoma Pharmaceuticals Announces Expansion of its Partner Network for Oral and Dental Products in the U.S. and China Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal …